期刊文献+

“融合科学”新范式及其对开放数据的要求 被引量:23

Convergence Science as a New Paradigm and Its Requirement for Open Data
原文传递
导出
摘要 “融合科学”是一种基于多学科融合来解决重大问题的科研新范式,被认为是人类解决重大经济社会问题的新机遇。推动“融合科学”意味着科研生态的根本性变革,其中一个最基础的方面是数据开放共享。文章总结了“融合科学”作为一种新科研范式的基本特征,提出了“融合科学”在基础数据方面的全学科、全流程和全景式等新要求,分析了数据开放共享支撑“融合科学”的成功实践,并展望了以开放数据推进实现“融合科学”的未来图景。 “Convergence Science”is a new paradigm of scientific research based on multi-disciplinary integration to solve grand problems,which is considered as a new opportunity for human beings to address major economic and social problems.Promoting“Convergence Science”means the fundamental change of scientific research ecology,one of the most basic aspects is the open sharing of data.Based on the basic characteristics of“Convergence Science”as a new paradigm of scientific research,this study puts forward new requirements of“Convergence Science”in terms of basic data,such as the whole disciplines,the whole processes and the full panorama,and then introduces the successful practice of open data supporting“Convergence Science”.Finally,it looks forward to the future prospect of promoting“Convergence Science”with“open data”.
作者 肖小溪 甘泉 蒋芳 陈捷 李晓轩 XIAO Xiaoxi;GAN Quan;JIANG Fang;CHEN Jie;LI Xiaoxuan(Institutes of Science and Development,Chinese Academy of Sciences,Beijing 100190,China;Bureau of Development Planning,Chinese Academy of Sciences,Beijing 100864,China;School of Public Policy and Management,University of Chinese Academy of Sciences,Beijing 100049,China)
出处 《中国科学院院刊》 CSSCI CSCD 北大核心 2020年第1期3-10,共8页 Bulletin of Chinese Academy of Sciences
基金 中国科学院战略研究专项(GHJ-ZLZX-2019-32-2) 中国科学院科技战略咨询研究院青年基金项目(Y9X1761Q01) 国家自然科学基金项目(71804176)
关键词 融合科学 开放数据 新范式 convergence science open data new paradigm
  • 相关文献

参考文献6

二级参考文献43

  • 1戴淑燕,黄新建.可持续发展协调度的评价方法分析[J].科技与管理,2004,6(6):22-23. 被引量:30
  • 2刘耀彬,宋学锋.改革开放以来中国工业化与城市化协调度分析[J].科技导报,2005,23(2):48-51. 被引量:40
  • 3吴凯,谢明.黄淮海平原农业综合开发的效益和粮食增产潜力[J].地理研究,1996,15(3):70-76. 被引量:3
  • 4李金颖.经济-电力-环境系统协调度分析[J].统计与决策,2006,22(6):50-51. 被引量:8
  • 5Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer.Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Homeopathy . 2012
  • 6Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncology . 2010 (2)
  • 7Adrian G. Sacher,Pasi A. J?nne,Geoffrey R. Oxnard.Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer[J]. Cancer . 2014 (15)
  • 8Ingrid Torjesen.Genomes of 100?000 people will be sequenced to create an open access research resource[J]. BMJ . 2013 (nov0)
  • 9Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncology . 2012 (3)
  • 10HelenaSkalnikova,JanMotlik,Suresh JivanGadher,HanaKovarova.Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines[J]. Proteomics . 2011 (4)

共引文献126

同被引文献424

引证文献23

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部